

Review Form 1.7

Journal Name:	Asian Journal of Medical Principles and Clinical Practice
Manuscript Number:	Ms_AJMPCP_108647
Title of the Manuscript:	Therapeutic Approach of Sodium Glucose Co-TransporterInhibitors to reduce Mortality and Morbidity in Type 2 DM Patients with Cardio Vascular Disorders
Type of the Article	Review Article

Review Form 1.7

PART 1: Review Comments

	Reviewer's comment	Author's comment (if agreed with reviewer, correct the manuscript and highlight that part in the manuscript. It is mandatory that authors should write his/her feedback here)
<p>Compulsory REVISION comments</p> <p>1. Is the manuscript important for scientific community? (Please write few sentences on this manuscript)</p> <p>2. Is the title of the article suitable? (If not please suggest an alternative title)</p> <p>3. Is the abstract of the article comprehensive?</p> <p>4. Are subsections and structure of the manuscript appropriate?</p> <p>5. Do you think the manuscript is scientifically correct?</p> <p>6. Are the references sufficient and recent? If you have suggestion of additional references, please mention in the review form.</p> <p><u>(Apart from above mentioned 6 points, reviewers are free to provide additional suggestions/comments)</u></p>	<p>Yes, this is an important, emerging new therapeutic option for heart failure pts regardless of the presence of diabetes</p> <p>Yes</p> <p>Yes</p> <p>Yes</p> <p>No as there a lot of grammatical/translator errors that negate the scientific facts</p> <p>No there are many more recent trials based on which FDA recommendations have been updated: 1. Zinman B, Wanner C, Lachin JM, et al. for the EMPA-REG OUTCOME investigators. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373:2117-2128.</p> <p>2. Neal B, Perkovic V, Mahaffey KW et al. for the CANVAS Program Collaborative Group. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med.2017;377:644-657</p> <p>3. Perkovic V, jardine MJ, Neal B et al, for CREDENCE Trial Investigators. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N Engl J Med.2019;380:2295-2306.</p> <p>The quality of English is very poor. For example, in the Abstract, the spelling of Diabetes is wrong; the line, "whose of 102 patients," appears to be incomplete, and there are many more. SGLT 2 should be expanded in the abstract itself at first appearance. T2DM is a "multifractional " disease, this spelling is wrong. The authors state that FDA rejected dapagliflozin in 2012. This is factually wrong. Reference 1 is quoted as saying that diabetes is oldest metabolic disorder since 1988??? The quoted reference says it has been recorded since 2000AD. The entire "overall remarks" section makes no sense.</p>	
<p>Minor REVISION comments</p> <p>1. Is language/English quality of the article suitable for scholarly communications?</p>	<p>ALL OUTDATED REFERENCES QUOTED, NEED TO INCLUDE MORE RECENT STUDIES.</p>	
<p>Optional/General comments</p>		

[Review Form 1.7](#)

PART 2:

	Reviewer's comment	Author's comment <i>(if agreed with reviewer, correct the manuscript and highlight that part in the manuscript. It is mandatory that authors should write his/her feedback here)</i>
Are there ethical issues in this manuscript?	<i>(If yes, Kindly please write down the ethical issues here in details)</i>	

Reviewer Details:

Name:	Anirban Kundu
Department, University & Country	Shree Aggarsain International Hospital, India